Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients With Elevated Serum Prostate-specific Antigen Is Not Clinically Beneficial: A Randomized Controlled Clinical Trial

Urology

Volumn 90, Issue , 2016, Pages 32-38

  Greiman, Alyssa ^a   Shah, Jaimin ^a   Bhavsar, Robin ^a   Armeson, Kent ^a   Caulder, Susan ^a   Jones, Rabun ^a   Keane, Thomas E ^a   Clarke, Harry S ^a   Savage, Stephen J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; PROSTATE SPECIFIC ANTIGEN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; FOLLOW UP; HUMAN; IMAGE GUIDED BIOPSY; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT DURATION; BLOOD; DRUG EFFECTS; MICROBIOLOGY; MIDDLE AGED; PROSTATITIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATITIS;

EID: 84977653721     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2015.11.046     Document Type: Article

References (30)

1. 1 Nadji, M., Tabej, S.J., Castro, A., et al. Prostate-specific antigen: an immunohistologic parker for prostatic neoplasms. Cancer 48 (1981), 1229–1232.
2. 2 Catalona, W.J., Smith, D.S., Ratliff, T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. NEJM 324 (1991), 1156–1161.
3. 3 Stamey, T.A., Yang, N., Hay, A.R., McNeal, J.E., Freiha, F.S., Redwine, E., Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. NEJM 317 (1987), 909–916.
4. 4 Hudson, M.A., Bahnson, R.R., Catalona, J.W., Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142 (1989), 1011–1017.
5. 5 Kilpelainen, T.P., Tammela, T.L., Roobol, M., et al. False-positive screening results in the European randomized study of screening for prostate cancer. Eur J Cancer 47 (2011), 2698–2705.
6. 6 Croswell, J.M., Kramer, B.S., Kreimer, A.R., et al. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med 7 (2009), 212–222.
7. 7 Kilpelainen, T.P., Tammela, T.L., Maattanen, L., et al. False-positive screening results in the finnish prostate cancer screening trial. Br J Cancer 102 (2010), 469–474.
8. 8 Raaijmakers, R., Wildhagen, M.F., Ito, K., et al. Prostate-specific antigen change in the European randomized study of screening for prostate cancer, section Rotterdam. Urology 65 (2004), 316–320.
9. 9 Yuan, J.J., Coplen, D.E., Petros, J.A., et al. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol 147 (1992), 810–814.
10. 10 Dalton, D.L., Elevated serum prostate specific antigen due to acute bacterial prostatitis. Urology 33 (1989), 465–466.
11. 11 Neal, D.E. Jr, Clejan, S., Sarma, D., Moon, T.D., Prostate specific antigen and prostatitis. Effect of prostatitis on serum PSA in the human and nonhuman primate. Prostate 20 (1992), 105–111.
12. 12 Bahson, R.R., Elevation of prostate specific antigen from bacillus calmette-guerin-induced granulomatous prostatitis. J Urol 146 (1991), 1368–1369.
13. 13 Nadler, R.B., Humphrey, P.A., Smith, D.S., et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 154 (1995), 407–413.
14. 14 Schaeffer, J.A., Ju, S.C., Tennenberg, A.M., Kahn, J.B., Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol 174 (2005), 161–164.
15. 15 Bozeman, C.B., Carver, B.S., Eastham, J.A., Venable, D.D., Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol 167 (2002), 1723–1726.
16. 16 Topac, H., Goktas, S., Basal, S., et al. A prospective controlled study to determine the duration of antibiotherapy in the patients with elevated serum psa levels. Minerva Urol Nefrol 1827-1758, 2014.
17. 17 Erol, H., Beder, N., Caliskan, T., et al. Can the effect of antibiotherapy and anti-inflammatory therapy on serum PSA levels discriminate between benign and malign prostatic pathologies?. Urol Int 76 (2006), 20–26.
18. 18 Shtricker, A., Shefi, S., Ringel, A., Gillon, G., PSA levels of 4.0-10 ng/ml and negative digital rectal examination: antibiotic therapy versus immediate prostate biopsy. Int Braz J Urol 35 (2009), 551–558.
19. 19 Eggener, S., Large, M., Gerber, G., et al. Empiric antibiotics for an elevated prostate-specific antigen (PSA) level: a randomized, prospective controlled multi-institutional trial. BJU Int 112 (2013), 925–929.
20. 20 Fandella, A., Benvenuto, S., Guidoni, E., et al. Empiric antibiotics therapy for mildly elevated prostate specific antigen: helpful to avoid unnecessary biopsies?. Arch Ital Urol Androl 86 (2014), 202–204.
21. 21 Baltaci, S., Suer, S., Haliloğlu, A.H., et al. Effectiveness of antibiotics given to asymptomatic men for increased prostate specific antigen. J Urol 191 (2009), 129–132.
22. 22 Faydaci, G., Eryildirim, B., Tarhan, F., et al. Does antibiotherapy prevent unnecessary prostate biopsies in patients with high PSA values?. Actas Urol Esp 36 (2012), 243–248.
23. 23 Bruyere, F., Amine Lakmichi, M., PSA interest and prostatitis: literature review. Prog Urol 23 (2013), 1377–1381.
24. 24 Eastham, J.A., Riedel, E., Scardino, P.T., et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 289 (2003), 2695–2700.
25. 25 Cochran, W.G., Subsampling with units of unequal size. Cochran, W.G., (eds.) Sampling Techniques, 3rd ed, 1977, John Wiley and Sons, New York, NY, 319–320.
26. 26 Wolf, A.M., Wender, R.C., Etzioni, R.B., et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 60 (2010), 70–98.
27. 27 Stopiglia, R.M., Ferreira, U., Silva, M.M., et al. Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial. J Urol 183 (2010), 940–945.
28. 28 Loeb, S., Martin, S.G., Broyles, D.L., et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol 193 (2015), 1163–1169.
29. 29 Sieczkowski, M., Gibas, A., Bronk, M., et al. Fluoroquinolone-based antimicrobial prophylaxis in patients undergoing transrectal ultrasound-guided prostate biopsy. Eur J Clin Microbiol Infect Dis 34 (2015), 1815–1821.
30. 30 Cohen, J.E., Landis, P., Trock, B.J., et al. Fluoroquinolone resistance in the rectal carriage of men in an active surveillance cohort: longitudinal analysis. J Urol 193 (2015), 552–556.